Pharmacokinetics and pharmacodynamics of aprepitant for the prevention of postoperative nausea and vomiting in pediatric subjects

This phase IIb trial evaluated aprepitant dosing for PONV prevention in 220 pediatric surgical patients, demonstrating dose-dependent pharmacokinetics and >80% complete response rates across all treatment groups. The study supports aprepitant as a well-tolerated antiemetic option in children undergoing general anesthesia.